28399-82-8

Usage

Uses

Used in Pharmaceutical Industry:
2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester is used as a synthetic intermediate for the production of oxadiazaspirodecanones and other ketone functional related compounds. These compounds are known to act as M1 muscarinic agonists, which have potential applications in the treatment of various neurological and cognitive disorders, such as Alzheimer's disease and schizophrenia.
In the synthesis of these compounds, 2-(1-Methyl-4-piperidinylidene)acetic Acid Ethyl Ester plays a crucial role in providing the necessary structural elements and functional groups that enable the formation of the desired pharmacologically active molecules. Its versatility in chemical reactions and compatibility with various synthetic routes make it a valuable component in the development of novel therapeutic agents.

InChI:InChI=1/C10H17NO2/c1-3-13-10(12)8-9-4-6-11(2)7-5-9/h8H,3-7H2,1-2H3

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 931-20-4 1-methylpiperidin-2-one 

Downstream Products

• 123318-91-2 2-ethyl-8-methyl-1-oxa-8-azaspiro<4.5>decan-3-one 
• 67686-05-9 (1-methyl-[4]piperidyl)-acetic acid ethyl ester 
• 132041-83-9 (-)-2-ethyl-8-methyl-1-oxa-8-azaspiro<4.5>decan-3-one 
• 132041-83-9 (+)-2-ethyl-8-methyl-1-oxa-8-azaspiro<4.5>decan-3-one 
• 132041-81-7 (S)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro<4,5>decane 

Relevant academic research and scientific papers

COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES

The present disclosure relates to compounds according to Formula (I), treating diseases.

ROR-GAMMA INHIBITORS

The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES

Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least o

Indazole derivatives having monocyclic amine

An indazole compound having the formula (I): wherein: R1 is hydrogen, C1 -C6 alkyl, C3 -C6 alkenyl or C3 -C6 cycloalkyl; Q is carbonyl, thiocarbonyl or methylene; and R2 is a group of the formula (II) or (IV); STR1 wherein R1 is C1 -C6 alkyl, C3 -C6 alkenyl or benzyl, of which a phenyl group thereof is optionally mono- or di-substituted by the same or different halogen or methoxy; m is 0 to 2; n and o is 1 or 2. The compound exhibits 5-HT4 receptor agonist activity.

Synthesis of bridgehead nitrogen heterocycles via cyclization of α- ammonio 5-hexenyl radicals

Ring-closure of the 2,2-dimethyl-2-azonia-5-hexenyl radical (4) proceeds smoothly and efficiently to give the 5-exo isomer essentially quantitatively, in accordance with predictions based on MP4SDTQ/6-31G* ab initio calculations on the thermodynamic stability of α-ammonio radicals. The corresponding 5-hexynyl radical species 15 and its 6-phenyl derivative 19 display similar behavior affording the analogous 5-exo-3- methylenepyrrolidinium salts in high yield. In none of these cases were the products of reduction were detected. All of the radical intermediates were generated conveniently by treatment of the iodomethyl and/or phenylselenomethyl salts with tributyltin hydride. Application of this procedure to monocyclic precursors such as 1-methyl-1-iodomethyl-4-methylene- 1-azoniacyclohexyl iodide (31) provided an attractive entry into quaternary derivatives of the 1-azabicyclo[2.2.1]heptyl system in good yield via a three-step sequence from 1-methylpiperidone. Dequaternization of the bicyclic salts so obtained unexpectedly leads to rupture of one of the rings rather than loss of the N-methyl group. The 1-azabicyclo[2.2.1]heptane could be accessed readily via tin hydride-induced cyclization of the corresponding N- phenylethylammonium salt 54, followed by Hofmann elimination with potassium tert-butoxide.

Synthesis of a new series of N-substituted-3-[1-alkyl(aryl)-4- piperidyl]azetidin-2-ones as possible muscarinic agents

A new series of N-substituted-3-[1-alkyl(aryl)-4-piperidyl]azetidin-2- ones 2a-j structurally related to the previously reported 2,7- diazaspiro[3,5]nonan-1-ones 1 have been synthesized and tested for their activity as muscarinic agents, both in vitro and in vivo. Preliminary pharmacological results showed that compounds 2 are devoid of significant cholinergic properties.